2014年8月30日讯 /生物谷BIOON/ --导读：阿斯利康近来喜讯不断，药物管线遍地开花，令投资者对其前景重燃希望。近日启动火爆PD-L1免疫疗法MEDI-4736结直肠癌II期临床，该药为旗帜产品，位列《全球重磅TOP 15》榜单， ...

Cabozantinib flops against prostate cancer, forcing big jobs cuts at ExelixisSeptember 1, 2014 | By John CarrollLate on Monday evening Exelixis put out the word that its crucial late-stage study of ca ...

刚刚在2013年痛失第一宝座的辉瑞可能连第二的位置都保不住了。从上半年各大公司的业绩看，罗氏、赛诺菲和默沙东都有超过颓势辉瑞的可能。让我们一起来看看各大公司都有哪些看家本领，未来发展会有哪些看点吧！诺华主 ...

大型生物技术公司在美国争相提交新药注册申请，这些产品随后会获准上市。医药市场研究机构EvaluatePharma精选全球顶级Ⅲ期临床试验药物，发现大公司“重磅炸弹”级新药竞争依旧激烈，百时美施贵宝、默沙东、赛诺菲、 ...

大智慧阿思达克通讯社9月2日讯，国家食药监总局（CFDA）网站信息显示，华北制药（600812.SH）申报的3.1类抗生素药物非达霉素原料药及片剂临床申请获受理。非达霉素目前在国内尚无生产企业，华北制药是国内第二个申报 ...

阿斯利康昨天官网宣布的Brilinta的实验数据，对心肌梗死的ST段效果迅速、明显。 直接把官网信息转过来 New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in ...

靶向药物也称“靶向治疗药物”或“标靶药物”，是一类只针对某一些特殊组织、细胞起作用的药物。最初靶向药物是被作为抗癌药物而开发的，但随着其发展，靶向药物的功效不仅仅局限于抗癌，已经广泛应用于类风湿、器官 ...

　　智飞生物9月1日晚间公告，在CFDA8月29日公示的药品GMP认证审查公示中，公司自主研发的AC群脑膜炎球菌（结合）b型流感嗜血杆菌（结合）联合疫苗（简称“AC-Hib疫苗”）和A群C群脑膜炎球菌多糖结合疫苗（简称“AC ...

Novo Nordisk picks diabetes-ridden Mexico for first Ryzodeg launchSeptember 2, 2014 | By Tracy StatonMexico is high on Novo Nordisk's priority list. Earlier this year, the company said it would target ...

Novartis sees 'most exciting launch' ever with megablockbuster-to-be heart drug September 2, 2014 | By Tracy StatonPharma executives tend to be circumspect when they talk about drug launches. After al ...

September 2, 2014Lundbeck announces availability of NORTHERA™ in the U.S.Northera™ (droxidopa) is approved by the FDA for treatment of Neurogenic Orthostatic Hypotension (NOH), a disorder ...

诺华诺德于09.02宣布，公司将暂停所有炎症性疾病药物研发，加大糖尿病领域的投入。　　公司之前于8月7日宣布暂停类风湿性关节炎新药白细胞介素-20抗体研发。公司称，研发受挫将会拖延公司进入炎症性疾病领域时间至20 ...

Sanofi's ($SNY) eyeing the top spot in the world vaccines market, and new Phase III results for its dengue jab may just help it get there. The positive results bode well for the candidate's shot at an ...

AstraZeneca's Soriot brushes off chatter about new Pfizer bid September 3, 2014 | By Arlene WeintraubWith rampant speculation that Pfizer ($PFE) might renew its effort to buy AstraZeneca ($AZN), one m ...

Teva trounces patent on AstraZeneca's Symbicort, opening up U.K. copycat launch September 3, 2014 | By Carly HelfandRing up another win for Teva ($TEVA) in its fight to roll out a generic of AstraZene ...